Arphio is an orphan pharmaceutical company that expands global patient access to rare disease treatments. The company secures rights to therapies with limited market availability and leverages its regulatory expertise to make them accessible to a wider patient population.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of individuals worldwide are affected by rare diseases, with a significant unmet need for accessible treatments. Many existing therapies are only available in limited geographic regions, and patients often face diagnostic delays and challenges in accessing specialized medical care.
Solution
Arphio is an orphan pharmaceutical company dedicated to improving global patient access to critical treatments for rare diseases. The company partners with leading specialists to identify and secure rights to therapies that are either in development or currently marketed in select countries. By leveraging its international market reach and regulatory expertise, Arphio makes these vital medications available to a broader patient population. This approach addresses the systemic barriers that prevent many rare disease patients from receiving necessary care.
Target Audience
Arphio's primary customers are patients and caregivers affected by rare diseases, as well as pharmaceutical companies seeking to expand the global reach of their orphan drug portfolios.
Features
- Identification and in-licensing of orphan drugs with limited market availability.
- Global regulatory submission and product launch capabilities across diverse healthcare systems.
- Expertise in genetic, hematology, and oncology rare disease therapeutic areas.
- Strategic partnerships with industry specialists for product development and market access.
- Focus on improving diagnostic pathways and patient awareness for rare conditions.